Transcatheter Aortic Valve Implantation in Degenerate Failing Aortic Homograft Root Replacements  by Chan, Pak Hei et al.
Journal of the American College of Cardiology Vol. 58, No. 16, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc.CORRESPONDENCE
Research
Correspondence Transcatheter Aortic Valve Implantation inDegenerate Failing Aortic Homograft Root ReplacementsTo the Editor: As with all bioprosthetic aortic valve substitutes,
homografts are prone to late degeneration characterized by dense
calcification and valve dysfunction. Reoperation in patients with
prior homograft aortic root replacement may carry a substantial
risk, particularly in elderly patients and patients with significant
comorbidities. Even in relatively fit patients, it can be technically
challenging, especially where there have been multiple previous
procedures or when there is calcification around the coronary ostia.
Transcatheter aortic valve implantation (TAVI) has become a
recognized treatment for patients with severe aortic stenosis (AS)
who are at high risk from conventional surgery. A small number of
reports (1,2) have described the use of TAVI as a valve-in-valve
procedure for structural degeneration of bioprostheses, predomi-
nantly in stented prostheses.
We describe the first series utilizing TAVI with a self-
expanding prosthesis to treat patients with structural degeneration
in a prior homograft aortic root replacement.
All TAVI procedures were performed under general anesthesia
with transesophageal echocardiography (TEE) guidance. Tempo-
rary right ventricular and right atrial pacing wires were placed
through the right internal jugular vein. The right femoral artery
was intubated with an 18-F Cook sheath after pre-closure with
10-F Prostar (Abbott Vascular Devices, Redwood City, Califor-
nia). The contralateral common femoral artery was cannulated
with a 6-F sheath with a 5-F pigtail catheter advancing to aortic
root. All arterial cannulation was undertaken utilizing ultrasound
guidance. For the left subclavian artery (LSCA) approach (in 1
patient with unsuitable iliofemoral system), the LSCA was ex-
posed by a left infraclavicular incision and cannulated directly with
an 18-F Cook sheath. The remainder of the procedure was similar
to the transfemoral approach.
The aortic valve was crossed with a soft-tipped straight 0.035-
inch wire within a 5-F Amplatz-Left-1 (Cordis Corp., Miami,
Florida) catheter. A pre-shaped SuperStiff-Amplatz guidewire
(Boston Scientific Corp., Natick, Massachusetts) was placed into
the left ventricular apex. Balloon pre-dilation of the homograft was
deliberately avoided. Under fluoroscopic and (specifically) TEE
guidance, a Medtronic CoreValve was positioned across the
homograft. The initial two-thirds of the deployment was effected
under rapid ventricular pacing at between 120 and 180 beats/min
(dependent upon the individual hemodynamic situation). Both TEE
and aortography were performed post-deployment to verify device
position and performance. The 18-F Cook sheath was removed
under ventricular pacing at 120 beats/min (to lower systolic
blood pressure) with deployment of pre-laid Prostar in all cases
(the LSCA was repaired by direct suture). Post-decannulation
angiography of the access site was effected in all patients. Before
discharge, a transthoracic echocardiogram was performed.This series consists of 5 consecutive patients. Patient character-
istics, procedural details, and outcome were listed in Table 1.
Device success, defined as successful deployment of CoreValve
prosthesis in optimal aortic position with 2 paraprosthetic
aortic regurgitation (AR) and successful retrieval of delivery
system, was 80%. In 1 patient, the first device was deployed too
deep (ventricular) in position with significant paravalvular regur-
gitation. A second device was deployed during the same procedure
such that 100% procedural success was achieved at the end of the
initial procedure in all patients. All patients had marked symp-
tomatic improvement with no more than mild AR at follow-up.
Mean aortic gradient was 24.0  16.5 mm Hg before TAVI and
8.2  2.8 mm Hg post-procedurally (p  0.07). There were no
access site complications, stroke, requirement for pacemaker, or
other complications (according to Valve Academic Research Con-
sortium definitions [3]). Short- and mid-term clinical outcomes
were satisfactory.
Several aspects of the procedure are worthy of highlighting.
Knowledge of implantation technique of the homograft and its
precise size are of pivotal importance. Multislice computed tomog-
raphy gives a clear picture of the root anatomy and geometry, the
distribution of calcium, and most importantly, an accurate mea-
surement of annular size. Significant distortion of root anatomy is
not infrequently encountered in these patients, and was a feature to
a greater or lesser extent in all of our patients. Balloon valvuloplasty
was deliberately avoided principally to avoid the creation of free
AR with hemodynamic compromise. Valvuloplasty is not neces-
sary to effect successful deployment in these patients. The less
bulky calcifications in patients with homograft roots (as compared
with native calcific aortic stenosis) reduces the risk of coronary
obstruction. However, low-lying coronary ostia and rigid, less
capacious aortic sinuses may increase the risk of coronary obstruc-
tion. Therefore, this risk in this subset of patients has to be
individually assessed.
The size-26 Medtronic CoreValve, recommended for 20 to
23 mm (native) annulus, was implanted in all patients. It would be
unusual to have a large homograft available for the initial implan-
tation. This and the healing/calcification process will almost always
result in a small aortic root. The size-26 will be suitable for the vast
majority in this setting. With smaller sizes of homograft, there may
be a relative degree of over-sizing of the prosthesis, as in our
patients. In some ways, this is a desirable feature given the
pathophysiological condition of severe AR and the need to effect
secure implantation/fixation with a substantial reduction in the
regurgitation.
The deployment and accurate positioning of the prosthesis is
challenging owing to a general paucity of anatomic landmarks on
fluoroscopy and severe AR leading to device instability. TEE was
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October 11, 2011:1729–32used to guide valve positioning to a much greater extent than in
patients with calcific aortic stenosis, aided by the very frequent use
of low-volume root injections. Valve stability during deployment is
dramatically enhanced by rapid ventricular pacing to reduce not
only pressure but also the antegrade stroke and regurgitant volume
per beat. In our view, the configuration, mode of deployment, and
method of fixation of the self-expanding CoreValve offer attractive
features in the setting of severe AR within a failing stentless aortic
bioprosthesis, such as an aortic homograft.
This is the first series to demonstrate the feasibility of using
TAVI with the self-expanding Medtronic CoreValves to treat
patients with severe AR due to structural degeneration of a prior
aortic homograft root replacement. The early results are encour-
aging; however, owing to the small size of the study, further studies
are recommended to evaluate the role of this approach.
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Patient Characteristics, Procedural Details, and Clinical OutcomesTable 1 Patien Charact ristics, Procedural Details, and Clinical Outcom
Patient #1 Pa
Age, yrs 78
Sex M
NYHA functional class III
Logistic EuroSCORE 26
STS score 4.2
No. of previous AVRs 2
Duration of last homografts, yrs 15
Pre-procedure
Homograft size, mm 24
CT annular size, mm 2424 2
Height of coronary ostia, R/L, mm 17/18.2 5
Rhythm SR
IHD, 70% stenosis No
LV ejection fraction, % 65
AV mean gradient, mm Hg 27
AR severity Severe S
Procedure detail
Access route TF
CoreValve size, mm 26
Post-implant
AR severity Trivial
AV peak gradient, mm Hg 8
Need PPM? No
Procedural success Yes
Hospital/ICU stay, days 6/1
Pre-discharge TTE, AR severity No AR
Follow-up, days 90
NYHA functional class I
Follow-up TTE
AR severity No AR
AV peak gradient, mm Hg 9
LV ejection fraction, % 65
*Patient had pre-existing permanent pacemaker for sick sinus syndrome. †Patient had severe per
first valve deployment resulting in significant paraprosthetic aortic regurgitation (AR), valve-in-valv
calcium at the root resulted in CoreValve appearing mildly constrained; the mean gradient was re
requiring prolonged in-patient care and urological consultations.
AV aortic valve; AVR aortic valve replacement; CT computed tomography; EuroSCORE Euro
 left; LV left ventricular; N/A not available; NYHA New York Heart Association; PPM new p
TE  transthoracic echocardiography.*Neil Moat, MBBS, MS*Transcatheter Valve Programme
Royal Brompton Hospital
Sydney Street
London SW3 6NP
United Kingdom
E-mail: N.Moat@rbht.nhs.uk
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